



IFW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37945-0054

Applicant(s): Angus George DALGLEISH *et al.*

Confirmation No.: 6757

Appl. No.: 10/624,889

Examiner: Sheela Jitendra Huff

Filing Date: July 23, 2003

Art Unit: 1642

Title: HUMAN PROSTATE CELL LINES IN CANCER TREATMENT

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.


The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Applicants believe that the instant Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits under 37 CFR §1.97(b)(3), therefore, no fee is required in connection with its filing.

English translations of the foreign-language documents may not be readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.


Respectfully submitted,



John P. Isacson
Reg. No. 33,715

July 12, 2004
Date

HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, D.C. 20006
Phone: (202) 912-2000
Fax: (202) 912-2020
Customer No. 26633



Sheet 1 of 2		PTO/SB/08A		ATTY DOCKET NO. 37945-0054		SERIAL NO. 10/624,889	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Angus George DALGLEISH <i>et al.</i>			
				FILING DATE July 23, 2004		GROUP 1642	
Date Submitted: July 12, 2004							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,699,483	3/2/04	DALGLEISH ET AL.	424	277.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A02	WO93/06867	4/93	WIPO			
	A03	WO97/24132	7/10/97	WIPO			
	A04	WO97/282255	8/7/97	WIPO			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A05	ABLIN	J. Cancer Res. Clin. Oncol. 123: 583-594 (1997)				
	A06	BERTHON	Intl J Oncology, 6(2): 333-343 (1995)				
	A07	BOON	Adv Can Res 58: 177-210 (1992)				
	A08	BRENNER ET AL.	Journal of Urology, pgs. 1575-1579 (1995) (abstract only)				
	A09	BRIGHT ET AL.	Cancer Research (57)(1): 995-1002 (1997)				
	A10	CURTI	Crit. Rev, in Oncology/Hematology 14:29-39 (1993)				
	A11	DERMER	Bio/Technology 12:320 (1994)				
	A12	DIEDERICHSEN et al.	Oncology Reports 5: 823-826 (1998)				
	A13	DILLMAN et al.	Cancer Biotherapy & Radiopharmaceuticals 15(2): 161-168 (2000)				
	A14	DREXLER ET AL.	Leukemia and Lymphoma 9:1-25 (1993)				
	A15	EMBLETON ET AL.	Immunol Ser 23:181-207 (1984)				
	A16	ENGEL et al.	Scand. J. Immunol. 45: 463-470 (1997)				
	A17	ESPARAZA et al.	J. of Immunology 131(5): 2117-2121 (1983)				
	A18	FENTON et al.	J. of Immunotherapy 19(5): 364-374 1996)				
	A19	FOGEL et al.	J. Natl. Cancer Inst. 62(3):585-588 (1979)				
	A20	FRESHNEY	Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p4 (1983)				
	A21	GORELIK ET AL.	Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only)				
	A22	GURA	Science 278:1041-1042 (1997)				
	A23	HARTWELL ET AL.	Science 278:1064-1068 (1997)				
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 2 PTO/SB/08A		ATTY DOCKET NO. 37945-0054		SERIAL NO. 10/624,889	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Angus George DALGLEISH <i>et al.</i>			
		FILING DATE July 23, 2004		GROUP 1642	
Date Submitted: July 12, 2004					
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A24	HROUDA et al.	BJU International 86: 742-748 (2000)		
	A25	HSU	Tissue Culture Methods and Applications, Kruse and Patterson, Eds., Academic Press, NY, pgs. 764767 (1973)		
	A26	JÄGER et al.	Int. J. Cancer 71: 142-147 (1997)		
	A27	JAIN	Sci. Am. 271:58-65 (1994)		
	A28	KAYAGA et al.	Gene Therapy 6: 1475-1481 (1999)		
	A29	KUSUMOTO et al.	Cancer Immunol Immunother 50: 373-381 (2001)		
	A30	LEHNER et al.	Cancer Immunol Immunother 32: 173-178 (1990)		
	A31	MARBLE	Cancer Weekly Plus, p4(2) (1997)		
	A32	MORAN	American Medical News 42, 39, 23 (1999)		
	A33	SCHREIBER et al.	Human Gene Therapy 10: 983-993 (1999)		
	A34	TAMURA et al.	Science 278: 117-120 (1997)		
	A35	TRiest ET AL.	Clinical Cancer Res. 4(8): 2009-14 (1998)		
	A36	VERMORKEN et al.	The Lancet 353: 345-350 (1999)		
	A37	VIEWEG ET AL.	Cancer Research 54: 1760-1765 (1994)		
	A38	VOLPE	Cancer Genet Cytogenet 34: 125-134 (1988)		
	A39	WU ET AL.	Intl J cancer, 77(6): 887-94 (1998)		
EXAMINER			DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.